Home LiteratureArticle Details
PMID: 19812802 Published · ppublish English Journal Article Review

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

The Canadian journal of cardiology ·Vol. 25 ·No. 10 ·2009-10-00 ·Pages 567-79

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E

Abstract

The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.

MeSH Terms
Adult Canada Cardiovascular Diseases/etiology,prevention & control Congresses as Topic Diagnostic Techniques, Cardiovascular Dyslipidemias/complications,diagnosis,drug therapy Humans Hypolipidemic Agents/therapeutic use Practice Guidelines as Topic/standards Risk Assessment/methods Societies, Medical
Chemicals
Hypolipidemic Agents
Authors & Affiliations
23 authors, click to expand affiliations / ORCID
Genest Jacques
McGill University Health Centre, Montreal, Canada. [email protected]
McPherson Ruth
Frohlich Jiri
Anderson Todd
Campbell Norm
Carpentier André
Couture Patrick
Dufour Robert
Fodor George
Francis Gordon A
Grover Steven
Gupta Milan
Hegele Robert A
Lau David C
Leiter Lawrence
Lewis Gary F
Lonn Eva
Mancini G B John
Ng Dominic
Pearson Glen J
Sniderman Allan
Stone James A
Ur Ehud
References (74)
74 references, click to expand
  1. General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
    Circulation. 2008 Feb 12;117(6):743-53 PMID: 18212285
  2. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease.
    Clin Chem. 2009 Feb;55(2):378-84 PMID: 19106185
  3. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).
    Circulation. 2007 Jan 23;115(3):402-26 PMID: 17220398
  4. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
    N Engl J Med. 2004 Sep 23;351(13):1296-305 PMID: 15385656
  5. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    N Engl J Med. 2005 Apr 7;352(14):1425-35 PMID: 15755765
  6. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.
    Clin Gastroenterol Hepatol. 2008 Jan;6(1):41-5 PMID: 18063423
  7. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.
    Circulation. 2006 May 16;113(19):2363-72 PMID: 16702489
  8. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.
    Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251 PMID: 18997194
  9. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Am J Cardiol. 2008 Apr 17;101(8A):58B-62B PMID: 18375243
  10. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines.
    Curr Opin Lipidol. 2006 Dec;17(6):619-25 PMID: 17095905
  11. Metabolic syndrome associated with HIV and highly active antiretroviral therapy.
    Curr Diab Rep. 2009 Feb;9(1):37-42 PMID: 19192423
  12. Prevalence of class I, II and III obesity in Canada.
    CMAJ. 2006 Jan 17;174(2):156-7 PMID: 16415457
  13. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
    JAMA. 2007 Feb 14;297(6):611-9 PMID: 17299196
  14. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)
    Lancet. 2000 Jul 22;356(9226):279-84 PMID: 11071182
  15. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
    Ann Intern Med. 2007 May 1;146(9):640-8 PMID: 17470832
  16. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.
    N Engl J Med. 2007 Jun 7;356(23):2388-98 PMID: 17554120
  17. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.
    J Am Soc Echocardiogr. 2008 Feb;21(2):93-111; quiz 189-90 PMID: 18261694
  18. Class of antiretroviral drugs and the risk of myocardial infarction.
    N Engl J Med. 2007 Apr 26;356(17):1723-35 PMID: 17460226
  19. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    N Engl J Med. 2005 Jul 21;353(3):238-48 PMID: 16034009
  20. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    N Engl J Med. 2009 Apr 2;360(14):1395-407 PMID: 19332456
  21. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
    JAMA. 2008 Jul 9;300(2):197-208 PMID: 18612117
  22. Family history as a risk factor for primary cardiac arrest.
    Circulation. 1998 Jan 20;97(2):155-60 PMID: 9445167
  23. The metabolic syndrome--a new worldwide definition.
    Lancet. 2005 Sep 24-30;366(9491):1059-62 PMID: 16182882
  24. Effects of torcetrapib in patients at high risk for coronary events.
    N Engl J Med. 2007 Nov 22;357(21):2109-22 PMID: 17984165
  25. Homocysteine lowering with folic acid and B vitamins in vascular disease.
    N Engl J Med. 2006 Apr 13;354(15):1567-77 PMID: 16531613
  26. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
    Circulation. 2006 Mar 21;113(11):1406-14 PMID: 16534008
  27. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    JAMA. 2007 Feb 7;297(5):499-508 PMID: 17284700
  28. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
    N Engl J Med. 2008 Nov 20;359(21):2195-207 PMID: 18997196
  29. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
    Am J Cardiol. 2008 Jun 16;101(12A):51F-57F PMID: 18549872
  30. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.
    Circulation. 2003 Jan 28;107(3):391-7 PMID: 12551861
  31. Abdominal obesity and metabolic syndrome.
    Nature. 2006 Dec 14;444(7121):881-7 PMID: 17167477
  32. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.
    JAMA. 2008 Jun 4;299(21):2524-32 PMID: 18523221
  33. Rosuvastatin in older patients with systolic heart failure.
    N Engl J Med. 2007 Nov 29;357(22):2248-61 PMID: 17984166
  34. Diagnostic performance of coronary angiography by 64-row CT.
    N Engl J Med. 2008 Nov 27;359(22):2324-36 PMID: 19038879
  35. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Lancet. 2009 Apr 4;373(9670):1175-82 PMID: 19329177
  36. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    JAMA. 2005 Nov 16;294(19):2437-45 PMID: 16287954
  37. To drink or not to drink? That is the question.
    Circulation. 2007 Sep 11;116(11):1306-17 PMID: 17846344
  38. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    N Engl J Med. 1999 Aug 5;341(6):410-8 PMID: 10438259
  39. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Lancet. 2005 Nov 26;366(9500):1849-61 PMID: 16310551
  40. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis.
    Am J Med. 2006 Oct;119(10):812-9 PMID: 17000207
  41. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    Lancet. 2005 Oct 8;366(9493):1267-78 PMID: 16214597
  42. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Am J Cardiol. 2007 Oct 1;100(7):1047-51 PMID: 17884359
  43. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing.
    N Engl J Med. 2003 Jul 31;349(5):465-73 PMID: 12890846
  44. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).
    Am J Cardiol. 2008 Nov 15;102(10):1312-7 PMID: 18993147
  45. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus.
    Arthritis Rheum. 1999 Feb;42(2):338-46 PMID: 10025929
  46. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
    Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113 PMID: 17726407
  47. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis.
    Am J Gastroenterol. 2007 Mar;102(3):662-7 PMID: 17156143
  48. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring.
    JAMA. 2004 May 12;291(18):2204-11 PMID: 15138242
  49. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Am J Cardiol. 2008 Nov 15;102(10):1341-7 PMID: 18993152
  50. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis.
    Am Heart J. 2005 Dec;150(6):1276-81 PMID: 16338271
  51. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Lancet. 2002 Jul 6;360(9326):7-22 PMID: 12114036
  52. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.
    Arch Intern Med. 2007 Nov 26;167(21):2296-303 PMID: 18039987
  53. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.
    Circulation. 2000 Sep 5;102(10):1082-5 PMID: 10973834
  54. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Lancet. 2003 Apr 5;361(9364):1149-58 PMID: 12686036
  55. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2008 Oct 4;372(9645):1231-9 PMID: 18757089
  56. Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl.
    Am J Cardiol. 2009 Feb 1;103(3):350-4 PMID: 19166688
  57. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus.
    Arthritis Rheum. 2003 Sep;48(9):2519-23 PMID: 13130471
  58. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
    J Intern Med. 2006 Mar;259(3):247-58 PMID: 16476102
  59. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
    JAMA. 2005 Jul 20;294(3):326-33 PMID: 16030277
  60. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.
    N Engl J Med. 2009 Feb 26;360(9):859-73 PMID: 19246357
  61. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    N Engl J Med. 2007 Sep 27;357(13):1301-10 PMID: 17898099
  62. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association.
    Circulation. 2008 Oct 21;118(17):1768-75 PMID: 18824640
  63. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    N Engl J Med. 1995 Nov 16;333(20):1301-7 PMID: 7566020
  64. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
    Lancet. 2004 Sep 11-17;364(9438):937-52 PMID: 15364185
  65. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    N Engl J Med. 1987 Nov 12;317(20):1237-45 PMID: 3313041
  66. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Am J Cardiol. 2008 Nov 17;102(10 Suppl):1K-34K PMID: 19068318
  67. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.
    Curr Opin Lipidol. 1995 Dec;6(6):386-8 PMID: 8750253
  68. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.
    JAMA. 2007 Jan 24;297(4):367-79 PMID: 17244833
  69. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
    Can J Cardiol. 2006 Sep;22(11):913-27 PMID: 16971976
  70. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    JAMA. 1998 May 27;279(20):1615-22 PMID: 9613910
  71. High rates of the metabolic syndrome in a First Nations Community in western Canada: prevalence and determinants in adults and children.
    Int J Circumpolar Health. 2006 Dec;65(5):389-402 PMID: 17319084
  72. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    N Engl J Med. 2004 Apr 8;350(15):1495-504 PMID: 15007110
  73. Cardiovascular morbidity in psoriatic arthritis.
    Ann Rheum Dis. 2009 Jul;68(7):1131-5 PMID: 18697777
  74. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
    Circulation. 2003 Oct 28;108(17):2154-69 PMID: 14581387
Article Info
Journal
The Canadian journal of cardiology
Abbr.
Can J Cardiol
ISSN
1916-7075
DOI
10.1016/s0828-282x(09)70715-9
Email
[email protected]
Published
2009-10-00
Pages
567-79
Language
English
Region
England
NLM ID
8510280
PMCID
PMC2782500
Subset
IM
External Links
PubMed source DOI: 10.1016/s0828-282x(09)70715-9 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2